Noemi Reguart, MD, PhD · @NReguart“What a day for #SCLC! Two positive phase III ADC trials today at #WCLC26 ARTEMIS-008 and TAISHAN-302— and this may be just the beginning. Look at the pipeline 👇 The ADC era has finally arrived in SCLC. Bye bye, topotecan! 🚀”
View post ↗Read the full ARTEMIS-008 readout on KOL Pulse →Presented at WCLC 2026 in Seoul, the Phase III MAVERICK trial in limited or extensive stage small cell lung cancer (SCLC) showed no difference in preliminary overall survival between MRI surveillance alone versus MRI plus prophylactic cranial irradiation (PCI), with better cognitive failure-free survival favoring the MRI-alone arm. Looking ahead, potential FDA approvals in Q4 2026 include a first-in-class B7H3-targeted ADC for SCLC and a PD-1 x VEGF bispecific antibody for non-small-cell lung cancer (NSCLC).
“- Prelim OS with no difference in two arms - Better Cognitive failure free survival with MRI alone - This rests the case for PCI in SCLC.”
— @OncBrothers · MAVERICK trial results · View post ↗“The ADC era has finally arrived in SCLC. Bye bye, topotecan!”
— @NReguart · ARTEMIS-008 & TAISHAN-302 (B7-H3 ADCs) · View post ↗
“Notable potential approvals include a first-in-class B7H3-targeted ADC for small-cell lung cancer...and a PD1 x VEGF bispecific antibody for non-small-cell lung cancer”
— @NatRevDrugDisc · Future regulatory milestones · View post ↗Community oncologists are digesting the FDA approval of camizestrant (Etcamah) for HR-positive metastatic breast cancer with an emergent ESR1 mutation detected in ctDNA before radiographic progression - the first approval built on treating a resistance mutation ahead of imaging progression (SERENA-6). Separately, results of the ELEVATE combination study of elacestrant plus everolimus in ER-positive, HER2-negative previously treated advanced breast cancer were published in Clinical Cancer Research.
“Camizestrant is now @FDA ✅ for HR+ metastatic #breastcancer with emersion of mESR1 prior to progression.”
— @OncBrothers · Camizestrant (Etcamah) FDA approval · View post ↗
“First approval ever driven by ctDNA, not imaging. Molecular progression is now actionable in the US.”
— @JAMouabbi · SERENA-6 / ctDNA-guided approval · View post ↗Phase 1 results for the investigational GPC3-targeted CAR-T therapy TAK-102 in GPC3+ solid tumors (72.7% HCC) showed manageable safety with no DLTs, but limited efficacy, with a disease control rate of 45.5% consisting of stable disease. Separately, the new NEST-3 trial is now open in the US, evaluating neoadjuvant immunotherapy (BOT/BAL) for patients with mismatch repair proficient high-risk stage II/III colorectal cancer.
“For patients with mismatch repair proficient high risk stage 2/3 #ColorectalCancer, new clinical trial now open across multiple sites in US.”
— @pashtoonkasi · NEST-3 trial · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A re-analysis of the pivotal EV-301 trial data shows higher NECTIN4 expression was associated with improved response to enfortumab vedotin (ORR 45.8% vs 20.0%), a finding now undergoing prospective validation in the EVOKE trial. In prostate cancer, a Pan Prostate Cancer Group analysis of 959 genomes identified eight mutational footprints explaining 85% of cases, with four footprints associated with shorter time to metastasis. Discussions also center on the optimal sequencing of ¹⁷⁷Lu-PSMA-617 (Pluvicto) earlier in the treatment pathway and the limitations of PSMA PET/CT, which can miss microscopic nodal metastases despite its high accuracy.
“🎯 Membranous NECTIN4 predicts EV response and survival. Cytoplasmic NECTIN4 does not.”
— @niklas_kluemper · NECTIN4 biomarker · View post ↗
“PSMA PET/CT improves staging — but a negative scan does not equal absence of nodal disease.”
— @nataliagandur · PSMA PET/CT limitations · View post ↗
“Prostate cancer genomes look like chaos. Eight mutational footprints explain 85% of them.”
— @katy_beckermann · Prostate cancer genomics · View post ↗
“Despite a phase III study being published several months ago, tE2 remains absent from treatment guidelines.”
— @DavidBenjaminMD · Transdermal estradiol in prostate cancer · View post ↗A new randomized controlled trial from CoMMitTrials is evaluating an MRD-guided approach in newly diagnosed multiple myeloma, testing time-limited bispecific antibody therapy for MRD-positive patients and de-escalation of ASCT for MRD-negative patients after quad induction. In Waldenström Macroglobulinemia, a discrete choice experiment with 1455 patients found that response duration and temporary toxicity most influence patient treatment preferences. Additionally, sales projections for 2025 place Darzalex as the second highest-selling oncology drug worldwide.
“Such an exciting milestone for another groundbreaking RCT in newly diagnosed #myeloma from @CoMMitTrials testing time-limited BsAb therapy to improve outcomes in MRD-positive and de-escalating ASCT in MRD-negative patients after Quad induction!”
— @rajshekharucms · New Trial Design · View post ↗
“International discrete choice experiment in 1455 #Waldenström pts finds response duration & temporary toxicity most impact preferences, then SPM & persistent toxicity; administration mode & tx duration had less impact:”
— @Myeloma_Doc · Waldenström Patient Preferences · View post ↗
“The oncology blockbuster race in 2025: 💊 Keytruda leads at $31.6B, followed by Darzalex at an impressive $14.35B and Opdivo at $10B—remarkably, a #MultipleMyeloma therapy now ranks #2 among the world’s top-selling oncology drugs!”
— @Abdallah81MD · Darzalex Sales Projections · View post ↗📌 Amplified by @KolPulseAI
“TCEs have largely succeeded when they target "clean", lineage-restricted cells, which is why they've worked well in B-cell malignancies or multiple myeloma but struggled against shared antigens in solid tumors.”
— @andrewpannu · T-cell Engager Biology · View post ↗A phase 1 study of the investigational CD38xCD3 bispecific T-cell engager XmAb18968 in relapsed/refractory AML and T-ALL showed early activity, including MRD-negative remissions, with no grade ≥3 CRS or neurotoxicity. Separately, development of the investigational PRC2 inhibitor pociredir was discontinued following an FDA class-wide risk re-assessment related to secondary hematologic malignancies. Other new data includes a SEER analysis of MPN epidemiology and a retrospective comparison of conditioning regimens for autologous stem cell transplant in Primary CNS Lymphoma.
“In this phase 1 study, we observed encouraging early activity, including MRD-negative remissions, with no grade ≥3 CRS or neurotoxicity.”
— @TalhaBadarMD · XmAb18968 in AML/T-ALL · View post ↗